Literature DB >> 24910390

Homozygous TREM2 mutation in a family with atypical frontotemporal dementia.

Isabelle Le Ber1,2,3,4,5, Anne De Septenville1,2,3, Rita Guerreiro6, José Bras6, Agnès Camuzat1,2,3, Paola Caroppo1,2,3, Serena Lattante1,2,3, Philippe Couarch1,2,3, Edor Kabashi1,2,3, Kawtar Bouya-Ahmed1,2,3, Bruno Dubois1,2,3,4,5, Alexis Brice1,2,3,5,7.   

Abstract

TREM2 mutations were first identified in Nasu-Hakola disease, a rare autosomal recessive disease characterized by recurrent fractures because of bone cysts and presenile dementia. Recently, homozygous and compound heterozygous TREM2 mutations were identified in rare families with frontotemporal lobar degeneration (FTLD) but without bone involvement. We identified a p.Thr66Met heterozygous mutation in a new consanguineous Italian family. Two sibs had early onset autosomal recessive FTLD without severe bone disorders. Atypical signs were present in this family: early parietal and hippocampus involvement, parkinsonism, epilepsy, and corpus callosum thickness on brain magnetic resonance imaging. This study further demonstrates the implication of TREM2 mutations in FTLD phenotypes. It illustrates the variability of bone phenotype and underlines the frequency of atypical signs in TREM2 carriers. This and previous studies evidence that TREM2 mutation screening should be limited to autosomal recessive FTLD with atypical phenotypes characterized by: (1) a very young age at onset (20-50 years); (2) early parietal and hippocampal deficits; (3) the presence of seizures and parkinsonism; (4) suggestive extensive white matter lesions and corpus callosum thickness on brain magnetic resonance imaging.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Dementia; FTD; FTLD; Nasu-Hakola; PLOSL; TREM2

Mesh:

Substances:

Year:  2014        PMID: 24910390      PMCID: PMC4208293          DOI: 10.1016/j.neurobiolaging.2014.04.010

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  8 in total

1.  TREM2 mutations are rare in a French cohort of patients with frontotemporal dementia.

Authors:  Serena Lattante; Isabelle Le Ber; Agnès Camuzat; Sarah Dayan; Chloé Godard; Inge Van Bortel; Anne De Septenville; Sorana Ciura; Alexis Brice; Edor Kabashi
Journal:  Neurobiol Aging       Date:  2013-06-04       Impact factor: 4.673

2.  Cutting edge: TREM-2 attenuates macrophage activation.

Authors:  Isaiah R Turnbull; Susan Gilfillan; Marina Cella; Taiki Aoshi; Mark Miller; Laura Piccio; Maristela Hernandez; Marco Colonna
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

3.  TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease.

Authors:  Cyril Pottier; David Wallon; Stephane Rousseau; Anne Rovelet-Lecrux; Anne-Claire Richard; Adeline Rollin-Sillaire; Thierry Frebourg; Dominique Campion; Didier Hannequin
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease.

Authors:  Margarita Giraldo; Francisco Lopera; Ashley L Siniard; Jason J Corneveaux; Isabelle Schrauwen; Julian Carvajal; Claudia Muñoz; Manuel Ramirez-Restrepo; Chris Gaiteri; Amanda J Myers; Richard J Caselli; Kenneth S Kosik; Eric M Reiman; Matthew J Huentelman
Journal:  Neurobiol Aging       Date:  2013-04-09       Impact factor: 4.673

5.  Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement.

Authors:  Rita João Guerreiro; Ebba Lohmann; José Miguel Brás; Jesse Raphael Gibbs; Jonathan D Rohrer; Nicole Gurunlian; Burcu Dursun; Basar Bilgic; Hasmet Hanagasi; Hakan Gurvit; Murat Emre; Andrew Singleton; John Hardy
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

Review 6.  Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects.

Authors:  Marino Muxfeldt Bianchin; Heraldo M Capella; Daniel Loureiro Chaves; Mário Steindel; Edmundo C Grisard; Gerson Gandi Ganev; João Péricles da Silva Júnior; Schaeffer Neto Evaldo; Mônica Aparecida Poffo; Roger Walz; Carlos G Carlotti Júnior; Américo C Sakamoto
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

7.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

Review 8.  Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family.

Authors:  Rita Guerreiro; Basar Bilgic; Gamze Guven; José Brás; Jonathan Rohrer; Ebba Lohmann; Hasmet Hanagasi; Hakan Gurvit; Murat Emre
Journal:  Neurobiol Aging       Date:  2013-07-17       Impact factor: 4.673

  8 in total
  31 in total

Review 1.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

2.  Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples.

Authors:  Stefan Prokop; Kelly R Miller; Sergio R Labra; Rose M Pitkin; Kevt'her Hoxha; Sneha Narasimhan; Lakshmi Changolkar; Alyssa Rosenbloom; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2019-07-26       Impact factor: 17.088

3.  Novel susceptibility loci for Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Future Neurol       Date:  2015-12

Review 4.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

Review 5.  Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges?

Authors:  Stefan Prokop; Virginia M Y Lee; John Q Trojanowski
Journal:  Prog Mol Biol Transl Sci       Date:  2019-10-24       Impact factor: 3.622

6.  Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2).

Authors:  Yuka Atagi; Chia-Chen Liu; Meghan M Painter; Xiao-Fen Chen; Christophe Verbeeck; Honghua Zheng; Xia Li; Rosa Rademakers; Silvia S Kang; Huaxi Xu; Steven Younkin; Pritam Das; John D Fryer; Guojun Bu
Journal:  J Biol Chem       Date:  2015-09-15       Impact factor: 5.157

Review 7.  The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases.

Authors:  Jochen Walter
Journal:  J Biol Chem       Date:  2015-12-22       Impact factor: 5.157

8.  R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study.

Authors:  Olena Korvatska; James B Leverenz; Suman Jayadev; Pamela McMillan; Irina Kurtz; Xindi Guo; Malia Rumbaugh; Mark Matsushita; Santhosh Girirajan; Michael O Dorschner; Kostantin Kiianitsa; Chang-En Yu; Zoran Brkanac; Gwenn A Garden; Wendy H Raskind; Thomas D Bird
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

Review 9.  Parkinsonism, movement disorders and genetics in frontotemporal dementia.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

Review 10.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.